For patients with RANBP2-ALK fusion positive epithelioid inflammatory myofibroblastic sarcoma (eIMS), a malignant variant of ALK-fusion-positive IMT, CD30 and ALK combination therapy may have high therapeutic potency. The gene discussed is ALK; the disease is inflammatory myofibroblastic tumor.